Axsome Therapeutics

aid: axsome-therapeutics
url: https://raw.githubusercontent.com/api-evangelist/axsome-therapeutics/refs/heads/main/apis.yml
name: Axsome Therapeutics
type: Index
kind: contract
access: 3rd-Party
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Consuming
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/axsome-therapeutics.png
description: 'Axsome Therapeutics (NASDAQ: AXSM) is a biopharmaceutical company developing and delivering novel therapies
  for the management of central nervous system (CNS) disorders. Headquartered at One World Trade Center, New York, Axsome
  markets three FDA-approved products — Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol)
  for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, and Symbravo (meloxicam-rizatriptan) for the
  acute treatment of migraine — and is advancing a pipeline including AXS-05 for Alzheimer''s disease agitation and smoking
  cessation, AXS-12 (reboxetine) for narcolepsy, and AXS-14 (esreboxetine) for fibromyalgia. Axsome operates a corporate website
  and product / HCP microsites but does not expose a public developer API surface; this profile catalogs corporate, product,
  regulatory, and investor touchpoints rather than programmatic interfaces.'
tags:
- biopharmaceuticals
- Biotechnology
- Pharmaceuticals
- Healthcare
- Life Sciences
- Neuroscience
- Central Nervous System
- Depression
- Migraine
- Narcolepsy
- Alzheimers Disease Agitation
- Fibromyalgia
- Smoking Cessation
- Clinical Pipeline
- FDA Approved
tags_raw:
- Biopharmaceuticals
- Biotechnology
- Pharmaceuticals
- Healthcare
- Life Sciences
- Neuroscience
- Central Nervous System
- Depression
- Migraine
- Narcolepsy
- Alzheimers Disease Agitation
- Fibromyalgia
- Smoking Cessation
- Clinical Pipeline
- FDA Approved
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.23'
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
common:
- type: DomainSecurity
  url: security/axsome-therapeutics-domain-security.yml
- type: Website
  url: https://www.axsome.com/
- type: About
  url: https://www.axsome.com/about/
- type: Products
  url: https://www.axsome.com/products/
- type: Pipeline
  url: https://www.axsome.com/pipeline/
- type: Science
  url: https://www.axsome.com/science/
- type: Publications
  url: https://www.axsome.com/publications/
- type: MedicalInformation
  url: https://www.axsome.com/medical-information-us/
- type: MedicalInformationCanada
  url: https://www.axsome.com/medical-information-canada/
- type: ExpandedAccessPolicy
  url: https://www.axsome.com/expanded-access-policy/
- type: Careers
  url: https://www.axsome.com/careers/
- type: Investors
  url: https://www.axsome.com/investors/
- type: NewsRoom
  url: https://www.axsome.com/news-events/
- type: RSS
  url: https://www.axsome.com/feed/
- type: ContactUs
  url: https://www.axsome.com/contact-us/
- type: PrivacyPolicy
  url: https://www.axsome.com/privacy-notice/
- type: TermsOfService
  url: https://www.axsome.com/terms-of-use/
- type: StateDisclosures
  url: https://www.axsome.com/state-disclosures/
- type: IntellectualProperty
  url: https://www.axsome.com/intellectual-property/
- type: ManagementTeam
  url: https://www.axsome.com/management-team/
- type: BoardOfDirectors
  url: https://www.axsome.com/board-of-directors/
- type: LinkedIn
  url: https://www.linkedin.com/company/axsome-therapeutics
- type: StockSymbol
  url: https://www.nasdaq.com/market-activity/stocks/axsm
- type: SECFilings
  url: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001579428&type=10-K
- type: Vocabulary
  url: https://raw.githubusercontent.com/api-evangelist/axsome-therapeutics/refs/heads/main/vocabulary/axsome-therapeutics-vocabulary.yml
- type: JSONLD
  url: https://raw.githubusercontent.com/api-evangelist/axsome-therapeutics/refs/heads/main/json-ld/axsome-therapeutics-context.jsonld
- type: ProductsList
  data:
  - name: Auvelity
    genericName: Dextromethorphan and Bupropion
    indication: Major Depressive Disorder (MDD) in adults
    status: FDA Approved
    productSite: https://www.auvelity.com
    hcpSite: https://www.auvelityhcp.com
    notes: Approved by the FDA in August 2022; oral NMDA receptor antagonist and sigma-1 receptor agonist combined with a
      CYP2D6 inhibitor.
  - name: Sunosi
    genericName: Solriamfetol
    indication: Excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) in adults
    status: FDA Approved
    productSite: https://www.sunosi.com
    hcpSite: https://www.sunosihcp.com
    notes: Dopamine and norepinephrine reuptake inhibitor (DNRI); also approved in Canada and the European Union (EMA SmPC).
  - name: Symbravo
    genericName: Meloxicam and Rizatriptan
    indication: Acute treatment of migraine with or without aura in adults
    status: FDA Approved
    productSite: https://www.symbravo.com
    hcpSite: https://www.symbravohcp.com
    notes: FDA approved January 2025; multi-mechanistic, oral fixed-dose combination of an NSAID (meloxicam) and a 5-HT1B/1D
      receptor agonist (rizatriptan).
- type: PipelineList
  data:
  - name: AXS-05
    components: Dextromethorphan and Bupropion
    indication: Agitation associated with dementia due to Alzheimer's disease; smoking cessation
    status: Approved for Alzheimer's disease agitation; in development for additional indications
    mechanism: NMDA receptor antagonist and sigma-1 receptor agonist (dextromethorphan); CYP2D6 inhibitor and DNRI (bupropion)
  - name: AXS-12
    genericName: Reboxetine
    indication: Narcolepsy (cataplexy and excessive daytime sleepiness)
    status: Investigational; FDA Orphan Drug Designation for narcolepsy
    mechanism: Selective norepinephrine reuptake inhibitor (NRI)
  - name: AXS-14
    genericName: Esreboxetine
    indication: Fibromyalgia
    status: Investigational
    mechanism: Selective norepinephrine reuptake inhibitor (NRI), single enantiomer of reboxetine
- type: ConditionsInFocus
  data:
  - name: Depression
    url: https://www.axsome.com/depression/
  - name: Migraine
    url: https://www.axsome.com/migraine/
  - name: Alzheimer's Disease Agitation
    url: https://www.axsome.com/alzheimers-disease-agitation/
  - name: Excessive Daytime Sleepiness
    url: https://www.axsome.com/excessive-daytime-sleepiness/
  - name: Narcolepsy
    url: https://www.axsome.com/narcolepsy/
  - name: Fibromyalgia
    url: https://www.axsome.com/fibromyalgia/
  - name: Smoking Cessation
    url: https://www.axsome.com/smoking-cessation/
- type: Address
  data:
  - street: One World Trade Center
    city: New York
    state: NY
    postalCode: '10007'
    country: USA
- type: Features
  data:
  - name: CNS Therapeutic Focus
    description: Exclusive focus on central nervous system disorders spanning psychiatric, neurologic, and sleep-wake conditions.
  - name: Multi-Mechanistic Small Molecules
    description: Portfolio leverages combinations and single enantiomers acting on NMDA, sigma-1, monoamine reuptake, TAAR1,
      5-HT, and GABA targets.
  - name: Commercial Stage with Three Approved Products
    description: Auvelity, Sunosi, and Symbravo are commercially marketed in the United States with sales force and patient
      support infrastructure.
  - name: Active Late-Stage Pipeline
    description: Pipeline candidates AXS-05, AXS-12, and AXS-14 address Alzheimer's disease agitation, narcolepsy, fibromyalgia,
      and smoking cessation.
  - name: Investor Disclosure
    description: Quarterly earnings, SEC filings (10-K, 10-Q, 8-K), webcasts, presentations, and analyst coverage published
      on the corporate site and EDGAR.
  - name: Medical Information Services
    description: U.S. and Canada medical-information request channels for healthcare professionals and patients.
- type: UseCases
  data:
  - name: Healthcare Professional Prescribing
    description: HCP microsites for each marketed product provide prescribing information, dosing, safety, and access support.
  - name: Patient Access and Adherence
    description: Patient-facing brand sites with medication guides, copay assistance, and condition education.
  - name: Investor Relations
    description: Public disclosures, regulatory filings, and press releases for shareholders, analysts, and financial-data
      consumers.
  - name: Scientific Communication
    description: Publications, congress presentations, and medical-affairs touchpoints for the clinical and scientific community.
  - name: Clinical Trial Engagement
    description: Expanded Access Policy and trial-related communications for investigators and patients seeking access to
      investigational therapies.
- type: Integrations
  data:
  - name: U.S. Food and Drug Administration (FDA)
    description: Regulatory submissions and approvals for NDA, sNDA, and post-marketing commitments covering Auvelity, Sunosi,
      Symbravo, and AXS-05.
  - name: European Medicines Agency (EMA)
    description: Sunosi (solriamfetol) maintains EMA authorization with SmPC and PIL published on the EMA website.
  - name: Health Canada
    description: Sunosi (solriamfetol) is approved in Canada with English and French product monographs and prescribing information.
  - name: NASDAQ / U.S. SEC
    description: Listed on NASDAQ as AXSM; periodic and current reports filed via EDGAR.
  - name: Specialty Pharmacy Networks
    description: U.S. distribution of branded CNS therapies through specialty and retail pharmacy partners.
  - name: Patient Support and Copay Programs
    description: Brand-specific patient support, copay assistance, and access services delivered via HCP and patient microsites.
apis: []